<SEC-DOCUMENT>0001610618-23-000022.txt : 20230323
<SEC-HEADER>0001610618-23-000022.hdr.sgml : 20230323
<ACCEPTANCE-DATETIME>20230323070511
ACCESSION NUMBER:		0001610618-23-000022
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230323
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230323
DATE AS OF CHANGE:		20230323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cidara Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001610618
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				461537286
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36912
		FILM NUMBER:		23754437

	BUSINESS ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-752-6170

	MAIL ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	K2 THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20140611
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cdtx-20230323.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:ac5471f4-923c-4743-a365-58c179d0f224,g:2afb46bd-f5c2-4434-9f77-277200747c2a,d:6d39ebf75f784b79852ec4ba7c04e853--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cdtx-20230323</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:EntityCentralIndexKey" id="f-22">0001610618</ix:nonNumeric><ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cdtx-20230323.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-23</xbrli:startDate><xbrli:endDate>2023-03-23</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i6d39ebf75f784b79852ec4ba7c04e853_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:12pt;text-align:center;text-indent:234pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center;text-indent:234pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">March&#160;23, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:EntityRegistrantName" id="f-3">Cidara Therapeutics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:234pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:EntityFileNumber" id="f-5">001-36912</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:EntityTaxIdentificationNumber" id="f-6">46-1537286</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:EntityAddressAddressLine1" id="f-7">6310 Nancy Ridge Drive,</ix:nonNumeric> <ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:EntityAddressAddressLine2" id="f-8">Suite 101</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:EntityAddressCityOrTown" id="f-9">San Diego,</ix:nonNumeric> <ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">California</ix:nonNumeric> <ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:EntityAddressPostalZipCode" id="f-11">92121</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:CityAreaCode" id="f-12">858</ix:nonNumeric>) <ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:LocalPhoneNumber" id="f-13">752-6170</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:Security12bTitle" id="f-18">Common Stock, Par Value $0.0001 Per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:TradingSymbol" id="f-19">CDTX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div style="margin-bottom:10pt;padding-left:121.5pt;text-indent:-121.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this report, &#8220;Cidara Therapeutics,&#8221; &#8220;Cidara,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Cidara Therapeutics, Inc.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;23, 2023, we issued a press release reporting our financial results for the fourth quarter and year ended December&#160;31, 2022.&#160;The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with General Instruction B-2 of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit&#160;99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex991-2023x03x23.htm">Press release issued March 23, 2023, reporting financial results for the fourth quarter and year ended December 31, 2022.</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:40.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.755%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cidara Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date: March 23, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey Stein, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey Stein, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991-2023x03x23.htm
<DESCRIPTION>EARNINGS RELEASE
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic228fcc9bdde4f1aaf42da0fbb75247e_1"></div><div style="min-height:50pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 99.1</font></div></div><div><img alt="cidaralogoa.jpg" src="cidaralogoa.jpg" style="height:103px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">SAN DIEGO, March&#160;23, 2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> &#8212; Cidara Therapeutics, Inc. (Nasdaq&#58; CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the three months and full year ended December&#160;31, 2022 and provided an update on its corporate activities and product pipeline.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;We have completed a transformational 2022 for Cidara and are carrying that momentum into 2023 with the recent U.S. Food and Drug Administration (FDA) approval of rezafungin for the treatment of candidemia and invasive candidiasis in adult patients with limited or no alternative treatment options. This approval enables Cidara to receive a $20.0&#160;million regulatory milestone payment under the terms of our agreement with Melinta Therapeutics,&#8221; said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. &#8220;Rezafungin is the first new drug in this indication in over a decade and our U.S. commercial partner, Melinta, is well-positioned to bring rezafungin to the U.S. market. Importantly, under the terms of our agreement with Melinta, Cidara is eligible to receive up to $40.0&#160;million in additional regulatory milestones, and up to $370.0&#160;million in commercial milestones, plus tiered royalties in the low double digits to mid-teens on U.S. net sales of rezafungin. These expected revenues would help advance our Cloudbreak&#174; drug-Fc conjugate (DFC) platform programs and the completion of our ongoing global Phase 3 ReSPECT prophylaxis study.&#8221;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dr. Stein continued, &#8220;We are also very pleased with the progress of our Cloudbreak DFC programs. We recently announced promising Phase 2a data for our lead influenza DFC, CD388, partnered with Janssen Pharmaceuticals. In addition, we announced the nomination of our first oncology DFC candidate, CBO-212, and presented preclinical data at the ESMO-TAT conference. We are currently conducting investigational new drug (IND)-enabling activities for CD421, which is an enhanced version of CBO-212. We look forward to providing further updates on these programs later this year as well as data from new oncology and antiviral programs.&#8221;</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recent Corporate Highlights</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Together with Melinta Therapeutics, announced FDA Approval of REZZAYO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On March 22, 2023, the FDA approved REZZAYO for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade, and is the only available once-weekly echinocandin. Cidara is eligible to receive a $20.0&#160;million regulatory milestone payment under the terms of our agreement with Melinta in connection with the FDA&#8217;s approval of REZZAYO.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Raised $19.5&#160;million from concurrent but separate public offerings&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In March 2023, Cidara sold and issued 11,086,000 shares of its common stock and 286,000 shares of its Series X Convertible Preferred stock in two concurrent but separate underwritten public offerings. The gross proceeds to Cidara from these offerings, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $19.5&#160;million.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Raised $8.9&#160;million from at-the-market offering&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> During the period from January 1, 2023, through March 20, 2023, Cidara sold 6,158,799 shares of common stock for gross proceeds of approximately $8.9&#160;million before deducting placement agent fees, under a controlled equity offering sales agreement with Cantor Fitzgerald &#38; Co.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Announced interim Phase 2a data assessing the safety and efficacy of a single dose of CD388 in an influenza challenge model&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> In March 2023, Cidara announced efficacy and safety data from a planned interim analysis of the ongoing Phase 2a trial evaluating the pre-exposure prophylactic activity of CD388 against the H3N2 influenza A virus strain, as of a February 13, 2023 data cut-off. As evidenced by animal efficacy studies, CD388 has the potential to be a long-acting antiviral drug designed to deliver universal prevention of seasonal and pandemic influenza A and B strains. The planned interim analysis of our Phase 2a study provided preliminary evidence that CD388 may effectively prevent influenza and supports our belief in the potential of DFCs from our Cloudbreak platform. The study is being conducted under an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson &#38; Johnson, to develop and commercialize DFCs for the prevention of seasonal and pandemic influenza.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Presented at the ESMO Targeted Anticancer Therapies Congress&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> In March 2023, Cidara presented preclinical data on a CD73-targeting DFC candidate, from the Cloudbreak platform, at the ESMO Targeted Anticancer Therapies Congress (ESMO TAT). The presented preclinical studies evaluated the functional activity, internalization and inhibition of CD73 in both cell-free and cell-based assays.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Regained compliance with Nasdaq listing requirements&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> In February 2023, Cidara received formal notice from The Nasdaq Stock Market, LLC (Nasdaq) Hearings Panel (the Panel) that Cidara had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), subject to a discretionary Panel Monitor until November 9, 2023.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Expanded relationship with WuXi XDC&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> In February 2023, Cidara and WuXi XDC announced an expansion of their existing collaboration in which WuXi XDC will provide IND-enabling chemistry, manufacturing and controls (CMC) development services for Cidara&#8217;s oncology DFC program.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Together with Melinta Therapeutics, announced FDA Advisory Committee recommendation to approve rezafungin for the treatment of candidemia and invasive candidiasis&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> In January 2023, the FDA Antimicrobial Drugs Advisory Committee voted favorably 14 to 1 that Cidara provided sufficient evidence in its New Drug Application (NDA) to support a favorable benefit-risk assessment for a limited use indication for rezafungin for the treatment of candidemia and invasive candidiasis in adult patients with limited or no alternative treatment options.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Nominated first oncology Cloudbreak candidate&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> In January 2023, Cidara announced it has selected its first oncology DFC candidate from the Company&#8217;s Cloudbreak platform. The candidate, CBO-212, is a first-in-class inhibitor of CD73, a cancer immunotherapy target that contributes to immune evasion by flooding the microenvironment surrounding tumors with adenosine, a potent immune cell suppressor. Cidara is currently advancing its lead oncology DFC candidate, CD421, which is an enhanced version of CBO-212 that confers reduced immunogenic properties, through IND-enabling studies.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Received first U.S. patent for lead influenza DFC, CD388&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> In December 2022, the U.S. Patent and Trademark Office issued U.S. Patent No. 11,510,992 for CD388, a highly potent, long-acting DFC designed to achieve universal prevention of seasonal and pandemic influenza. The patent, entitled Compositions and Methods for the Treatment of Viral Infections, is the first issued for CD388 and includes claims directed to the composition of matter of CD388. The patent is projected to expire in 2039, plus any available patent term extension.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Participated in the World Antiviral Congress&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> In December 2022, Dr. Stein participated in a panel discussion at the World Antiviral Congress. The panel discussed pandemic preparedness and therapeutic approaches, including predictions on the next viral threat, development of broad-spectrum drugs and platforms to engineer novel therapeutics.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Together with Melinta Therapeutics, announced peer-reviewed publication of results from the Phase 3 ReSTORE trial in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">The Lancet</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> In November 2022, results from the global Phase 3 pivotal ReSTORE trial of rezafungin for the treatment of candidemia and invasive candidiasis were published in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">The Lancet</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The publication, entitled, &#8220;Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE)&#58; a multicentre, double-blind, double-dummy, randomised phase 3 trial,&#8221; details the efficacy and safety of rezafungin, including the statistical noninferiority of once-weekly rezafungin compared to the current standard of care, once-daily caspofungin.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Presented at the Stifel Healthcare Conference&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> In November 2022, Dr. Stein presented at the Stifel Healthcare Conference. The presentation focused on Cidara&#8217;s Cloudbreak platform, which couples potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fourth Quarter and Full Year 2022 Financial Results</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Revenue totaled $10.2 million and $64.3 million for the three months and full year ended December&#160;31, 2022, respectively, compared with $7.2 million and $49.6 million for the same periods in 2021.</font></div><div style="margin-top:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Revenue for the year ended December&#160;31, 2022 included $25.9 million of revenue recognized upon transfer of an intellectual property license to Melinta in August 2022. The remaining revenue for the year ended December&#160;31, 2022 relates to the achievement of milestones and ongoing research and development and clinical supply services provided to Mundipharma, Janssen and Melinta of $14.3 million, $23.3 million and $0.8&#160;million, respectively.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Revenue for the year ended December&#160;31, 2021 included $27.0 million of revenue recognized upon transfer of an intellectual property license to Janssen in May 2021. The remaining revenue for the year ended December&#160;31, 2021 relates to the achievement of milestones and ongoing research and development and clinical supply services provided to Mundipharma and Janssen of $13.2 million and $9.4 million, respectively.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Cash and cash equivalents totaled&#160;$32.7 million&#160;as of&#160;December&#160;31, 2022, compared with cash, cash equivalents and restricted cash of&#160;$62.3 million&#160;as of&#160;December&#160;31, 2021.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">As of&#160;December&#160;31, 2022, Cidara had 72,470,440 shares of common stock outstanding, and 1,818,472 shares of Series X Convertible Preferred Stock outstanding, which are convertible into 18,184,720 shares of common stock.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Research and development expenses were&#160;$20.1 million&#160;and&#160;$75.5 million&#160;for the three months and full year ended&#160;December&#160;31, 2022, respectively, compared to&#160;$19.0 million and&#160;$73.1 million&#160;for the same periods in 2021. The increase in research and development expenses for the full year ended December&#160;31, 2022 compared to the full year ended December&#160;31, 2021 is primarily due to increased expense associated with our Cloudbreak antiviral platform, offset by lower clinical expenses associated with the rezafungin clinical trials and lower personnel costs.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">General and administrative expenses were&#160;$3.4 million and&#160;$18.5 million&#160;for the three months and full year ended&#160;December&#160;31, 2022, respectively, compared to&#160;$5.0 million and&#160;$18.7 million&#160;for the same periods in 2021. The decrease in general and administrative expenses is primarily due to lower consulting and personnel costs.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Net loss for the three months ended&#160;December&#160;31, 2022&#160;was&#160;$13.4 million, compared to a net loss of&#160;$16.8 million&#160;for the three months ended December&#160;31, 2021. Net loss for the full year ended&#160;December&#160;31, 2022&#160;was&#160;$29.8 million, compared to a net loss of $42.5&#160;million for the year ended December&#160;31, 2021.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Cidara Therapeutics</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cidara is developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases. The Company&#8217;s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to DFCs targeting viral and oncology diseases from Cidara&#8217;s proprietary Cloudbreak</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This release contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. &#8220;Forward-looking statements&#8221; describe future expectations, plans, results, or strategies and are generally preceded by words such as &#8220;anticipates,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;may,&#8221; &#8220;plan&#8221; or &#8220;will&#8221;. Forward-looking statements in this release include, but are not limited to, statements related to Melinta&#8217;s ability to bring rezafungin to the U.S. market, the completion of the ongoing global Phase 3 ReSPECT prophylaxis study, whether CD388, CD421, or any Cloudbreak DFC candidate will be safe or effective, whether we will submit an IND for CD421, and whether REZZAYO will be prescribed by physicians and reimbursed by public and private payors. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidara&#8217;s preclinical or clinical trials, delays in action by regulatory authorities due to limitations on inspections and other COVID-19-related effects, and impacts of the COVID-19 pandemic or other obstacles on the enrollment of patients or other aspects of CD388 development. These and other risks are identified under the caption &#8220;Risk Factors&#8221; in Cidara&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022 and other filings subsequently made with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management&#8217;s assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTOR CONTACT&#58;</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Brian Ritchie</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">LifeSci Advisors</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(212) 915-2578</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">britchie&#64;lifesciadvisors.com</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MEDIA CONTACT&#58;</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Patrick Bursey</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">LifeSci Communications</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(203) 430-9545</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">pbursey&#64;lifescicomms.com</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:125%">Three months ended<br>December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:125%">Year ended<br>December 31,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:125%">(In thousands, except share and per share data)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:125%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:125%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:125%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:125%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">Revenues&#58;</font></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:125%">(unaudited)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">Collaboration revenue</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">10,219&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">7,225&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">64,288&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">49,572&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">Total revenues</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">10,219&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">7,225&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">64,288&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">49,572&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">20,058&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">19,013&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">75,520&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">73,087&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">3,428&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">4,982&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">18,486&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">18,740&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">23,486&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">23,995&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">94,006&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">91,827&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(13,267)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(16,770)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(29,718)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(42,255)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">Other income (expense)&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">Interest income (expense), net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">162&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(33)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">191&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(212)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">Total other income (expense), net</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">162&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(33)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">191&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(212)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">Loss before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(13,105)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(16,803)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(29,527)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(42,467)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">Income tax expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(272)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(272)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">Net loss and comprehensive loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(13,377)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(16,803)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(29,799)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(42,467)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">Basic and diluted net loss per common share</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(0.19)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(0.26)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(0.43)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(0.81)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">Shares used to compute basic and diluted net loss per common share</font></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">71,895,890&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">64,475,463&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">69,857,698&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">52,453,452&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheet Data</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:70.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.866%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:125%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:125%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:125%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:125%">(In thousands)</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">Cash, cash equivalents, and restricted cash</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">32,731&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">62,273&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">Total assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">47,593&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">75,325&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">Term loan</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">2,591&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">50,497&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">53,752&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total stockholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8217;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> equity (deficit)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">(2,904)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">21,573&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cdtx-20230323.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:ac5471f4-923c-4743-a365-58c179d0f224,g:2afb46bd-f5c2-4434-9f77-277200747c2a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cdtx="http://cidara.com/20230323" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cidara.com/20230323">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20230323_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20230323_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://cidara.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cdtx-20230323_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:ac5471f4-923c-4743-a365-58c179d0f224,g:2afb46bd-f5c2-4434-9f77-277200747c2a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_c8c1a5a5-fdc5-485d-a1ed-230158fa7378_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_3eac36f5-9b27-4819-b78c-7d783cafbcc7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ed804654-df3e-4847-a9d0-5735765ea399_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_0d259f44-e380-4cfc-838b-a9bc15cafca9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_7c9be112-3f6d-4fce-96a4-4d958f73ef20_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7fbc4a87-f0d0-456e-8e33-778d6ba66ab1_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_2043ac9e-2637-4a87-a864-39a5a1cfdc00_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_864d0c70-2661-459f-b038-b272cbcf7ac8_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_9ee61530-1ca6-4610-93dd-769e88bd81ee_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_33e0b4da-02f7-411d-be58-e27a7686a630_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_18e70a9e-210c-4a3e-ac72-7da9ff490b7a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6a88cf29-cef7-4be3-842e-91b00e3f3f36_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_3521608f-1e8b-4b02-9e22-ae3aaf1a1d7e_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4b77e018-596a-416a-b7ec-d034fcd251cd_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_6f86ed7d-a7a4-49b5-a40b-120b93fe823f_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1430a632-0d57-4d4d-b28e-e8860503e3ed_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_07c1b473-e21b-4e30-b692-d170e11d7917_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b935ba66-5c6d-45d6-9a43-a9ee9b716222_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a4650bf8-d464-4845-866a-3a5043e25619_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9f471195-734d-4149-bac0-08fbd51d91e0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2818195b-30f3-4c76-8cfb-9012a0260821_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d1212869-d5af-46b6-9472-a23dc2b3869d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5b843dcf-ed96-4094-ad1d-9f7f40d644cc_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_eace43a9-afb5-43e6-9bf9-61c18ec0059d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cdtx-20230323_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:ac5471f4-923c-4743-a365-58c179d0f224,g:2afb46bd-f5c2-4434-9f77-277200747c2a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cidara.com/role/CoverPage" xlink:type="simple" xlink:href="cdtx-20230323.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://cidara.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5570f8c0-bb3f-4afd-894f-c9fd08a0ec01" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_DocumentType_5570f8c0-bb3f-4afd-894f-c9fd08a0ec01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b662ae79-7d3d-4ace-8a91-210443cb3915" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_DocumentPeriodEndDate_b662ae79-7d3d-4ace-8a91-210443cb3915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6ddbf3d0-9410-40df-84bb-9a311f7d1600" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_EntityRegistrantName_6ddbf3d0-9410-40df-84bb-9a311f7d1600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_445e377c-0e6c-415e-af7e-946c08dc28b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_445e377c-0e6c-415e-af7e-946c08dc28b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_88263947-60b3-4596-8ba1-23012cab111d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_EntityFileNumber_88263947-60b3-4596-8ba1-23012cab111d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6a52b1ff-d63a-4443-a435-f09a619f6093" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_EntityTaxIdentificationNumber_6a52b1ff-d63a-4443-a435-f09a619f6093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3ad1d4c0-c8d0-47c0-91e0-3228eb0aa349" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_EntityAddressAddressLine1_3ad1d4c0-c8d0-47c0-91e0-3228eb0aa349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_9efb1349-3ee5-485c-adfa-4aeb02f92bc2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_EntityAddressAddressLine2_9efb1349-3ee5-485c-adfa-4aeb02f92bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_80d660ad-add5-473f-b37f-e6b0912e8e9d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_EntityAddressCityOrTown_80d660ad-add5-473f-b37f-e6b0912e8e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_413a556a-91e7-453c-9afe-f088a894e5ad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_EntityAddressStateOrProvince_413a556a-91e7-453c-9afe-f088a894e5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a10f9f3b-eb16-4b0e-8844-68735860c760" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_EntityAddressPostalZipCode_a10f9f3b-eb16-4b0e-8844-68735860c760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3ab60208-88a1-489d-9b6d-8a3a33b1e8c5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_CityAreaCode_3ab60208-88a1-489d-9b6d-8a3a33b1e8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b1059896-cf16-4844-924e-839870af8356" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_LocalPhoneNumber_b1059896-cf16-4844-924e-839870af8356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_6222b8bd-45d9-420e-b497-356ae374e6b7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_WrittenCommunications_6222b8bd-45d9-420e-b497-356ae374e6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_11b76f32-beed-471c-9fcd-81f631a12c9c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_SolicitingMaterial_11b76f32-beed-471c-9fcd-81f631a12c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_971c5de8-8e70-4aae-8cb0-0404cb42a980" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_PreCommencementTenderOffer_971c5de8-8e70-4aae-8cb0-0404cb42a980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_31e085a1-6ecf-48b0-b674-e10c7b221b92" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_31e085a1-6ecf-48b0-b674-e10c7b221b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c71bd226-9bd4-4c92-b030-cb4da55a93f4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_Security12bTitle_c71bd226-9bd4-4c92-b030-cb4da55a93f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c71c3f71-b1cc-4a81-81c4-b220d5330fd9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_TradingSymbol_c71c3f71-b1cc-4a81-81c4-b220d5330fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8bcc13f2-c7f8-4880-9a3f-19665811873a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_SecurityExchangeName_8bcc13f2-c7f8-4880-9a3f-19665811873a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_87144d6a-fda6-484c-b0ce-5df7de924527" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_EntityEmergingGrowthCompany_87144d6a-fda6-484c-b0ce-5df7de924527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b572b73c-c32c-48dd-b605-06666d784c45" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_EntityCentralIndexKey_b572b73c-c32c-48dd-b605-06666d784c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d6ce5c32-2511-4e87-867d-809ce4ad1769" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924106a4-5761-4add-a5cb-2eccb729736a" xlink:to="loc_dei_AmendmentFlag_d6ce5c32-2511-4e87-867d-809ce4ad1769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>cidaralogoa.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cidaralogoa.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0!817AI9@  34T *@    @ ! ,"  (
M   2    /E$0  $    ! 0   %$1  0    !   N(U$2  0    !   N(P
M  !S4D="($E%0S8Q.38V+3(N,0#_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#Y;_X*I?MFW'[+'P6ATS0+CR/&'BXR6]E*I^:P@4#S;@>C#<JI_M-NYV$
M5^.5Q<27<\DLKO)+(Q=W<[F<GDDGN37U)_P6.^(-QXS_ &W]:T^21FMO"]C:
M:;;KGY0&A6X?CUWSL/P%?+%?@/&.:5,7F4X-^[3;BEZ:-_-_A;L?TYP%DU/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTL@'^W(SM_P*OT3PZP<YXV>)^S&-OFVOT3_ _*_%;,(4\OIX2_O3E>WE%/\
M5K\3M****_9#\#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI>77[GK^!OT445QGI!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<8_ZSY3_ -!$?O/LZBOD_1/^"U?[/^JNJS^(]8TT-U-SHMRP7_OVKUZ!X/\
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M;U*QTC2K%/,N;R\G6&"!<@99V("C) Y/>FDV[(4I**N]C0HKRO\ X;F^"_\
MT5?X=_\ A06O_P 71_PW-\%_^BK_  [_ /"@M?\ XNM_JE?^1_<SD_M#"_\
M/V/_ ($O\SU2BO+[7]MSX.7UU'##\5/A[+-,P1$77[4L[$X  W]2:]0K.I2G
M#XTUZJQM1Q%*K_"DI6[-/\@HHHK,V"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P U^*UZ,]_HHHKY4^_"BBB@ J&_OX-*L9KJZFAMK:W0R2RRN$CB0#)9F/
M'))Z4FIZG;Z+IMQ>7D\-K:6D333S2N$CA102S,3P  "23T K\?O^"C'_  4>
MU;]J;Q/=>&_#=U<:=\/+&79'$A,<FM,I_P!=-WV9&4C/ X)&[[O@Y_Q!0RNA
M[2IK)_#'O_DEU9]-PSPQB<YQ'LJ7NPC\4NB_S;Z(^MOVDO\ @M5X#^%M]<:7
MX)T^;QUJ4)*-=)+]FTU&Z?+(06EP?[JA3V>OE;QE_P %K/C1XCNF;3Y/#/A^
M'/RI::;YI ]S,TF3^ ^E?(U%?CN.XQS7$RO[1P7:.GX[_>S]XRW@/)<)!1=)
M5'U<_>O\ME\D?5GAW_@LU\<M$NEDN=5T'6$4Y,5WI$2JWU\GRV_(U]%? '_@
MNGH>OWL-C\1O#,N@M(0IU/2F:YME/J\+?O%4?[)D/M7YDT5G@^+LUP\N95G+
MRE[R_'7[FC;'<#Y+BH<LJ"B^\?=:^[3[TS^ASP)X_P!$^)_A:UUSP[JECK.D
MWR[X+JTE$D;^HR.A'0@\@\$ UL5^%_[&_P"VIXJ_8Y\?QZAI,TE[H-Y(O]JZ
M-)(1!?)T)']R4#[K@9'0Y7(/[5?!WXNZ'\=OAKI/BSPY=?;-)UB$2Q,1AXST
M:-Q_"ZL"K#L0:_7.&^)J.:TVK<M2.\?U7E^7W-_A?%G"%?):JE?FI2^&7Z/L
M_P 'NNJ734445]0?'A1110 4444 %%%?*G_!27_@I5I?[&/AO^P]$%KJWQ#U
M2'?:VCG=#ID9R!<3@?\ CJ<%L9.!UZ,+A:N(JJE15VSCQ^/H8.A+$8B5HK^K
M+NV>I_M5_MJ> ?V._"RW_B_5=M]<H6LM*M0);Z_(_N1Y&%SP7<JH/&<X!_+;
M]J?_ (+-_%+X[W%Q8^&;AOA[X=<E5ATV4F_F7_II<X# ^T00=CNZU\N?$CXE
MZ]\7_&E]XB\3:K>:UK6I2>9<75R^YW/8#LJ@<!0 %    &*PZ_2<KX;P^&2E
M57//N]EZ+]7^!^)YYQMC<=)TZ#=.GV6[]7^BT]2;4-1N-6OIKJZGFNKFX8O+
M+*Y>21CU+,>23ZFH:*Z3X;?!WQ9\8]7^P^$_#>N>([M<;H].LI+@QY[L5!"C
MW; KZ&4HQ5Y:(^.C"=27+%-M_-G-T5]6>!?^"+_Q\\9PI)<>&]+\/QR<J=3U
M6%6Q[K$9&'T(!KO+/_@@%\7IHMTWB;X=0L?X1>WC8^O^C5YT\ZP,'9U8_??\
MCV:7#.:U%>.'E\U;\['PO17W)??\$!?C#;INA\1_#FX_V1?WBL?SML?K7*^(
MO^"(OQZT16-KI/A[6,=K36(ES_W^\NE'.L!+:K'[[?F54X8S:&KP\ODK_E<^
M1:*]K\;_ /!.3XY?#U)&U'X8^*9$C^\UA;C4% ]<VY<8]^E>0:]X<U#PKJ+6
M>J6%YIMW']Z"Z@:&1?JK &NZEB*576G)2]&F>3B,'7H.U:#CZIK\SV#]A/XA
M^/K#]HWP3X:\(^+/$.A0Z]K=K:7$-G>.D#1/*OFL\6=C )N/*GI7[Z5^+?\
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M_L4[3_TINZ^FX3_W_P"3/B/$#_D4O_%']3XEHHHK]./PH_I(^'G_ "(&A_\
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MF&TDG]_3Y;!1117.=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;<XC5AZ/,P8>\!K\HZ_2.$<'[/"NN]YO\%_P;GXGXB9E[;'1PL=J:U]9:O\
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MX3NU;Z?:;0_S K]AJ_+N*HI9A)]TORM^A^\< U'+*(I])27XW_4****^</M
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M.ZC/I\IQ@2&-RH<>S !AZ@BN;K[E_P""[_P&_P"$ _:8TOQK:P[+'QU8#SV
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MU\_5] _\%3_^4@'Q*_Z_X?\ TFAKY^K]HRW_ '2E_AC^2/YESG_D85_\<O\
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M])H:^?J^@?\ @J?_ ,I /B5_U_P_^DT-?/U?M&6_[I2_PQ_)'\RYS_R,*_\
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MI+F*<8[XC=B!Z@5_0;!.ES"DD;+)'(H964Y5@>00:_FAK]T?^"4GQ^_X7_\
ML5^%[BXF\[5O#*G0-0R<MOMPHC8]R6@:%B3U):OG^,<'>,,5'IH_S7Z_>?8>
M&^96G4P,NOO+U6C_  M]Q]'T445\$?K04444 %?CS_P7L_Y/2TG_ +%.T_\
M2F[K]AJ_'G_@O9_R>EI/_8IVG_I3=U]-PG_O_P F?$>('_(I?^*/ZGQ+1117
MZ<?A1_21\//^1 T/_L'V_P#Z+6MBN'^"'Q;\*^/O NBIH7B;P_K3K8P*RV.H
MPW#*1&H((1CR/2NXK\/J1<9-25C^IL/4C.FG%W5@HHHK,V"BN=^('Q>\*?"B
MP:Z\3^)=!\/6ZKNWZC?Q6P(]M[#/T'6OD?\ :/\ ^"Y/PQ^&-I<6?@>"\\?:
MRH*I)&C6FG1MZM*XWOCKA$(/]X=:[,+E^)Q+M1@W^7W['FX_.,%@H\V)J*/E
M?7Y+=_<?5WQN^-WAK]GCX;ZAXK\6:E#IFCZ:F69CF2=_X8HUZO(Q& HZ^P!(
M_"+]L_\ :NUC]L;X[:EXNU16M;5@+72[#?N73[122D>>[')9CW9FQ@8 @_:C
M_;"\=_M?>,5U;QEJQN(K<M]BTZW!BL=/4]1%'D\GC+,2YP,L<#'E]?HN19"L
M$O:U-9O[DNR_5_T_QGBOBR69R5"BG&E%WUWD^[_1?-^15O0-"O/%.NV6F:=;
MRWFH:C.EK;01+N>>5V"HBCN2Q 'UJI7Z1?\ !%']@*XO-8M_C)XNL6BL[4,/
M#%K,G,\ARK7I!_A496/U)+#&U2?5S+'PP=!UI_)=WT1X.2Y35S'%QPU+KN^R
MZO\ R[O0^]OV1?@);_LR?LX^$_!,/EM-HUDHO)$^[-=.3).X]C(SXST&!VKT
MBBBOQVI4E4FZD]V[OYG](T*,*-.-*FK1BDEZ+1!11169J%%%% 'Q]_P6Q^/W
M_"HOV/I_#]K-Y>J^/KI=+0*<,+5<27##V*A(S[35^,%?87_!;'X_?\+=_; F
M\/VLWF:7X!M5TM IRINGQ)<,/<$I&?>&OCVOU?AS!_5\#&^\O>?SV_"Q_/W&
MF9?6\TGROW8>ZOEO^-PK]J?^"+GP&_X4]^QEI^L74/EZIXZN7UF4L/F$'^KM
MU_W3&OF#_KL:_(+X%?"F\^.?QE\,>#[#<+GQ%J4-B' SY*NX#R'V1=S'V4U_
M1-X9\.6?@_PWI^DZ="MOI^EVT=G;1+TBBC4(BCZ* *\KC#&<M*&&7VG=^BV_
M'\CZ#PWR[GQ%3&R6D5RKU>_W+\R]1117YZ?L(5^47_!??X#?\(S\8O"_Q"M(
M=MMXHLSIM\RC@7-OC8S'U>%E4>T!K]7:^=_^"I_P&_X7]^Q3XLLX(?.U3P_&
M-?T\ 9;S+8%G '<M"9D ]6%>OD6,^KXV$WL]'Z/_ "W/G>*\N^NY95II>\ES
M+U6OXJZ^9^$]6M$UFZ\.:S9ZA8S/;7MA,EQ;S(<-%(C!E8>X(!_"JM%?KN^C
M/YU3:=T?T4_LV_&6U_:$^ WA/QI9[!'X@TZ*YD1#D0S8VS1_\ D5U_X#7;U^
M>O\ P0&^/W_"0_"_Q3\.;R;=<>';D:MIZL>3;3_+*JCT250Q]YZ_0JOQO-,'
M]5Q4Z/1/3T>J_ _I;(<Q6.P%+$]6M?5:/\0HHHKSSU@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#G?BM\*?#_ ,;O &I>%_%&F6^K:)JT
M7E7%O*.O<,I'*LIP58$$$ @YK\@/VX_^"1'C;]FC4+S6O"=O>^,_ ^6D6:WB
M\R^TU.NV>)1E@!_RT0;<#+!.E?M#17K97G%? RO3UB]T]O\ @,^?S[AO"9I"
MU;2:VDMUY>:\ONL?S/GBBOWT^.W_  3L^#O[15U->>(O!6G+JLY+/J.G%K&Z
M=O[SM$5$A_ZZ!J^>_$7_  ;_ /POOKEGTWQ;XXT]&.?+EDMKA5]@?*4X^I-?
M:X?B[!S7[Q.+]+_E_D?F.*\.\RIR_<N,UZV?S3_S9^1]26MK+?W4<,$<DTTS
M!(XT4LSL>  !R2?05^NGA/\ X($?"?2+I9=5\2>-]853GR1<6]O&_P!=L1;\
MF%?2GP'_ &)?A9^S2RR^#O!NDZ;?*,?;Y5:ZO??$TI9U![A2![5.(XNPD%^Z
M3D_N7]?(K!^'>85)?[1*,%ZW?W+3\3\Z/V"?^"+_ (@^*.HV/B?XK6MUX;\+
MH5FBT9\QZCJ8Z@2#K!&>^<2$9 "Y#5^KWAOPYI_@_0+/2M*L[;3]-TZ%;>UM
M;>,1Q01J,*JJ.  !C%7:*^(S+-:^-GS57HMDME_7<_4LER'"Y72]GAUJ]Y/=
M_P# [)?F%%%%>:>T%%%% !1110 4444 %%%% !1110 445P'[2?[2?AC]ECX
M8W7BCQ1=&.WC/E6MK'@W%_,02L42GJQQDGHH!)( K.M6IT:;JU7:*U;?0VP^
M'J5ZD:-&+E*3LDMVSM]5U:UT+39KR^N;>SL[5#)-//((XXE'5F8X  ]37RS\
M;?\ @L;\(?A3=36>DW6I>-K^(E3_ &1$/LJM[SR%58>\8<5^<O[7O[>7CC]K
M_P 0R'5[R33/#<<FZST*TD(M80/NM)T\V3_;;H<[0H.*\3K\ISCQ$J.3IY=%
M)?S2W?HNGSOZ(_:<B\*Z2@JN:S;E_+%V2\F]W\K>K/T,U_\ X+ZZE+<M_9?P
MTL880>#=:RTK,/HL*@?3FKGA7_@OI)]I5=<^&J^23\TMCK/S*/9'BP?^^A7Y
MST5\TN-,Y4N;VW_DL?\ (^O?A_D#CR^P_P#)IW_]*/VF^ O_  51^#_QXNX;
M&/7)?"^K3D*EGKL:VOF-TPLH9HB2> -X8YZ5]'*P=01R#R".]?SEU]2?L-_\
M%/?%G[+6IV>BZY-=^)O >X1O8ROON--3^];.QX Z^63L/;:3NKZW)?$)RFJ6
M8Q27\R_5?JON/A^(/"U1@ZV52;:^Q+K_ (7I]S^\_9"BL/X<?$?1?BYX(TWQ
M'X=U"#5-&U:$36UQ$?E<="".JL"""IP5(((!%;E?J$)QG%2B[I[,_&ZE.4).
M$U9K1I[IA1115$A1110 4444 %%%% &;XQM#?^$=5@7[TUG-&/Q0BOYL:_I@
M(W#!K^;#Q?HC>&O%FJ::PPVGW<ML1Z%'*_TK[K@N7\:/^']3\I\3H_[O+_'_
M .VF=7O'_!,:Z%G^WM\,6/\ %JVS_OJ*1?ZUX/7K'[".MCP]^VC\*[EFVK_P
ME&GPL?023I&?_0J^PQT>;#5%_=?Y'YQE<N7&T9/I./YH_H(HHHK\5/Z="BBB
M@ HHHH **** "BBB@ HHHH **** /P@_X*G_ /*0#XE?]?\ #_Z30U\_5] _
M\%3_ /E(!\2O^O\ A_\ 2:&OGZOVC+?]TI?X8_DC^9<Y_P"1A7_QR_\ 2F>I
M?L._\GG?"?\ [&[2_P#TKBK^@ZOY\?V'?^3SOA/_ -C=I?\ Z5Q5_0=7Q/&7
M\>GZ/\S]0\-?]UK?XE^04445\:?I05^+?_!;_P#Y/QU+_L#V/_H!K]I*_%O_
M (+?_P#)^.I?]@>Q_P#0#7U'"/\ OS_PO\T?!^(G_(J7^-?DSY#J6Q_X_8?]
M]?YU%4MC_P ?L/\ OK_.OTP_$([G]+=%%%?A9_584444 %%%% !1110 55UJ
M\73M&N[AONP0O(?H%)JU7%_M'^)5\&_L\^/-79MJZ7X>U"[SZ;+:1OZ5=./-
M-175F=:HH4Y3?1-G\Z=%%%?N)_*YZW^P3;&Z_;7^%2@9QXIT]_\ OF=&_I7]
M M?@U_P2]T-O$/[?7PSMU&XQZFUS^$,$LI_] K]Y:_.^,I?[3"/]W]6?LOAK
M'_8JLO[_ .27^84445\>?HY\T?\ !6KX_?\ "A?V*O$AMYO)U;Q9CP_8X.&_
M?AO.8=^(%EP1T8K7X;5]V?\ !>/X_?\ "=_M%:/X%LYMUCX(L?-NE4\?;+D*
M[ ^NV$0X]"[BOA.OU/AG!^PP2D]YZ_+I^&OS/P3CG,OK6:2A%^[3]U>O7\=/
MD%?K=_P04^ W_"%_L^Z]X\NH=MYXSO\ [/:,P_Y=+7<F0?\ :F:8'U\M:_)_
MPSX<O/&/B33](TZ%KC4-4N8[.UB7K++(P1%'U8@5_1-\"OA39_ SX->&/!]A
MM-MX=TV&Q#@8\YD0!Y#[NVYC[L:X^+L9[/#1H+>;_!?\&QZ7AWEWM<;+%R6E
M-:>LM/RN=91117YP?M(4444 </\ M*?!NW_:#^ ?BSP7=; OB#39;:)W'RPS
M8W0R?\ D5&_X#7\[^KZ3<Z#JUU8WD,EO>64SP3Q.,-$ZDJRGW!!%?TL5^(O_
M  6&^ W_  I/]M;7;JWA\K2_&D:Z_;$#Y?,E)6X&?7SDD;'82+7VG!V,Y:D\
M,^NJ]5O^'Y'YCXD9=S4:>-BM8OE?H]5]SO\ >?+-?>G_  05^/W_  A?Q\UW
MP#>3;;/QG9?:;-6/'VRV#-@#_:A:4GU\I:^"ZZCX)_%.^^"'Q>\-^+M-S]L\
M.ZC#?(H./-"."T9]F7*GV8U]EF6$6)PTZ#ZK3UW7XGYKDN8/ XZGBEM%Z^CT
M?X7/Z.**S?!_BNQ\=^$M+US3)A<:;K%I%?6DHZ212H'1OQ5@:TJ_&FFG9G]+
MQDI*ZV"BBBD,*_'G_@O9_P GI:3_ -BG:?\ I3=U^PU?CS_P7L_Y/2TG_L4[
M3_TINZ^FX3_W_P"3/B/$#_D4O_%']3XEHHHK]./PH56*,&4D,#D$=JZGP]\=
MO''A)572?&7BK3%7[HM-6N(<?]\N*Y>2-H7*LK*RG!!&"*;4RC&2M)7+A4G!
MW@VO0].A_;7^,EO'M7XL?$@+TQ_PDMX<?^1*R]>_:B^)GBF-DU3XB>.M11A@
MK=:]=3 CZ-(:X6BLUAJ*=U!?<C>6.Q#5G4E][)+J[FO[AIIY))II#EG=BS,?
M<FHZ*DM;=KRYCA38&E8(I=PBY)QRS$ #W) %;'+N1U);6TE[<1PPQR333,$1
M$4LSL3@  <DD]J^YO@+_ ,$'OB-X\:WO/&NMZ+X-TV0!S#!(-2O6'7@1D0C(
M_B\QOH:^_OV5_P#@F_\ "W]DGR;S0=%_M/Q#&,'6]5(N;P'OY? 2+O\ ZM5)
M!P2:^=QW$V#H*U-\\NRV^_;[KGVF5<"YEBVI5E[./>6_RCO]]CXF_P""=_\
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M;>*=2UK4IFN=1U:ZEO;J5NLLLCEW8_5B36?117[,DDK(_FB4FW=GWE_P04^
MW_"9_M Z]X\NH=UGX,L/LUHQ'_+W=!DR#WVPK,#Z>8M?K=7S-_P2/^ W_"B_
MV)O#9N(?)U3Q;N\07F1AOWX7R1Z\0+%QV):OIFOR3/\ &?6,;.2V6B^7_!NS
M^A^$<N^IY73@U[TES/U>OX*R^04445XQ](%-FA6XA:.15DCD!5E89# ]013J
M* /Y[?VS/@8_[-W[3_C/P?Y;1VFEZB[6.?XK23$L!SW_ '3H#[@UYC7Z0_\
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M<)=VES"</#(A!5A^(Z'@]#Q7[P?L$?MD:7^VE\"K/Q!#Y-KX@T_;::[8(?\
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M-?DSY#J6Q_X_8?\ ?7^=15+8_P#'[#_OK_.OTP_$([G]+=%%%?A9_584444
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M%/!1>LGS/T6WWO\ (J5J>"O!^H_$/QCI6@Z1;M>:KK5W%8V<"G!EFD<(BY/
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MMBFU%-)6:5WN]T]M/O/Q/_X<K?M ?]"UI/\ X.K7_P"+H_X<K?M ?]"UI/\
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MF"BOQP_8C_X+*^,/V<M/L_#?C2WN/&WA&V B@=I<:EIT8X"QR-Q*@'1),$<
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M?$C+Y<U+'16EN5_FOS9^U>$^:1Y:V72>M^=>>RE]UE^)Y/1117Y:?LP4444
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MI9=5KQ^*UEZO1?=O\C\UR=QR:*L?V1=_\^MQ_P!^C_A1_9%W_P ^MQ_WZ/\
MA7[!='\Y<K/NS_@@G\!/^$R^/NO>/KN'=9^#;'[+9LP_Y>[D,N0?]F%90?3S
M5K];*^:_^"3?P#/P$_8I\,QW,'DZMXI#>(+X%<,#.%\I3W&(%B!!Z'=7TI7Y
M'GV,^L8V<ELM%Z+_ (-V?T-PEEOU+*Z=-KWI>\_5Z_@K+Y!1117CGT@4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOA;J%VO\+7>NI;G\0L#_ ,ZPQ_P<0:AYO_)*;/R^X_X2%L_G]G_I0!^GE%?
M_P (_P#@OU\/_%>IPVOB[PGKWA%9F"FZMYUU.WA]WPL<F/\ =1C[5]P> ?B!
MHGQ2\(V.O>'=4LM9T;4H_,MKNUE$D<HZ'D=""""#R""" 010!L4444 %%%%
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M#V.(XS[35^<O_!,+X-?\+O\ VWO VG2P^;8Z5>?VU>9&5$=J/-4-[-(L:?\
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M5M \C_"_Q<J1J68_8CP!UKR'0M;NO#.MV>I6,SV]]I\Z7-O*OWHI$8,K#W!
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M&&Q_Z^(__0A7]*E?S>_"OP]-XN^)_AO2;=6>XU35+6TC4#EFDE5 /S-?TA4
M%%%% !1110!^67_!PO\ \E,^&O\ V#+S_P!&QUY%_P $2O\ D_C1?^P7?_\
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M8>Q'%25_.1\+OC?XP^">LIJ'A'Q-K7AVZ5@Q:QNWB63V=0=KCV8$'TK]+?\
M@GE_P6;7XIZ]8>"?BQ]BT_6KQE@T_7XE$-O>R'A8[A!\L;L> ZX0DX(7J>3,
M.%L1AX.I2?.EOI9_=K^9Z.3<>X/&5%1KQ]G)[7=XOYZ6^:MYGZ%4445\N?=A
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7F_[9/\ R:%\5O\ L3]7_P#2*:O2*IZ_H-EXJT&^TO4K6"^T[4K>2UNK
M:9 \=Q$ZE71@>"K*2"#U!H _FKK^A+]BG_DS?X3?]B;I'_I%#6=_PP!\$?\
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M&OWXK@_B;^RY\.?C1X@CU;Q9X)\->(M3B@6V2ZO[".:58E+,$W,,X!9CCW-
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M/_ :^>]*T?QI^T_\6C#:PZQXO\8>)+DR.1F:XN9#U=B>BCNQPJ@=@*_9P?\
M!(#]G5;L3?\ "NUW YV_VWJ)0G_=^T8_#I7LOPB_9\\#_ 33)+3P;X5T3PY%
M, )6LK58Y9\=/,D^^^/]HF@#@/\ @GO^R2O[&O[-VF^%[B2&XUV\E;4M9GBY
MC>ZD"@JIZE4140'OM+8&[%>X444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ74M8U.0*BJ/DA3^*61NB1J.2QZ#WP*F<XPBY2=DBZ=.=22A!7;T274^\O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
L0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140687824227616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Mar. 23, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 23,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cidara Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-1537286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6310 Nancy Ridge Drive,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">752-6170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.0001 Per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CDTX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001610618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>cdtx-20230323_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cdtx-20230323.xsd" xlink:type="simple"/>
    <context id="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2023-03-23</startDate>
            <endDate>2023-03-23</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-22">0001610618</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-2">2023-03-23</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-3">Cidara Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-5">001-36912</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-6">46-1537286</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-7">6310 Nancy Ridge Drive,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-8">Suite 101</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-9">San Diego,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-10">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-11">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-12">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-13">752-6170</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-18">Common Stock, Par Value $0.0001 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-19">CDTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323"
      id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M1&^&'O7>;CS)=6S=#7\TR/A:S(7]-9L9N/(KE4BF0N52*V+$:NB-Z<TMZ[B
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "D.'=6&445]3<!   G @
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MZ]Q*N??P2K8<<XY_M/P!4$L#!!0    ( *0X=U8D'INBK0   /@!   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=
M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\
MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X
M\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].
MM.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " "D.'=699!YDAD!  #/ P
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M<' N>&UL4$L! A0#%     @ I#AW5D;6G4SN    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ I#AW5IE<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " "D.'=672*,IV0$   N$0  &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ I#AW5I^@&_"Q
M @  X@P   T              ( !IPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    " "D.'=6EXJ[',     3 @  "P              @ &##P  7W)E;',O
M+G)E;'-02P$"% ,4    " "D.'=6&445]3<!   G @  #P
M@ %L$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ I#AW5B0>FZ*M
M^ $  !H              ( !T!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ I#AW5F60>9(9 0  SP,  !,              ( !
MM1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  _Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cdtx-20230323.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="cdtx-20230323.htm">cdtx-20230323.htm</File>
    <File>cdtx-20230323.xsd</File>
    <File>cdtx-20230323_lab.xml</File>
    <File>cdtx-20230323_pre.xml</File>
    <File>ex991-2023x03x23.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cdtx-20230323.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "cdtx-20230323.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cdtx-20230323_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cdtx-20230323_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cdtx-20230323.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "cdtx",
   "nsuri": "http://cidara.com/20230323",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20230323.htm",
      "contextRef": "ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://cidara.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20230323.htm",
      "contextRef": "ia9883b0125ed432e9c392a2dc803564e_D20230323-20230323",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001610618-23-000022-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001610618-23-000022-xbrl.zip
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MXEXYD52*^@_S%+12M" U [6[,<[ 4D(Y]>S>X&%J?]9DX9M(!L@+!_LML.K
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M/D3.CD_/;&3,%**!96;2@:)\['TA#GO_H*^E!EZ[OE3BQ47Q<Z+/U11@; Z
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M\DHG!G]PK<6<SZ8Z+$@H&-2A(D)Z/$\RD$(2@Q0S+%*1,2XZKXGMFA];<'A
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M!U@YL%NJ4>1<K=>)YR54C41GE>'I#ZB:S4;M?W*'6$9(@]7>C:-6.I N-?@
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MT"R;E'NMJ=#A+IAX^@A&Z46OT=QGK6:CUFNWVN5>:T"V^:0H>5BN<+?8O;K
M>KO\@?7RO-[TXNSDZPF[_OG\Z\F7\U^N+TZO#/ F3U<VGLH#B8]ISHA.T'O
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M   1              "  0    !C9'1X+3(P,C,P,S(S+FAT;5!+ 0(4 Q0
M   ( *0X=U:3AFO1:P(  &D'   1              "  8 /  !C9'1X+3(P
M,C,P,S(S+GAS9%!+ 0(4 Q0    ( *0X=U9O[OT!N H  $)B   5
M      "  1H2  !C9'1X+3(P,C,P,S(S7VQA8BYX;6Q02P$"% ,4    " "D
M.'=6&[H"<=0&  #V,@  %0              @ $%'0  8V1T>"TR,#(S,#,R
M,U]P<F4N>&UL4$L! A0#%     @ I#AW5MW#I@P)(   U"(! !0
M     ( !#"0  &5X.3DQ+3(P,C-X,#-X,C,N:'1M4$L%!@     %  4 1@$
' $=$      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
